Cyclophosphamide in the therapy of rheumatoid arthritis and its complications;Rola cyklofosfamidu w leczeniu reumatoidalnego zapalenia stawów i jego powikłań

Polski Merkuriusz Lekarski

Volumn 22, Issue 132, 2007, Pages 566-570

  Trefler, Jakub ^a,b   Matyska Piekarska, Ewa ^a,b   Ła̧cki, Jan K ^a,b  

^a Instytut Reumatologii w Warszawie   (Poland)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Cyclophosphamide; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOPHOSPHAMIDE;

ARTICLE; HUMAN; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOPHOSPHAMIDE; HUMANS; TREATMENT OUTCOME;

EID: 34547359744     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Alepa F.P., Zvaifler N.J., Śliwiński A.J.: Immunologic effects of cyclophosphamide treatment in rheumatoid arthritis. Arthritis Rheum., 1970, 13, 754-760.
2. Amor B., Herson D, Cherot A., Delbarre F. i wsp.: Follow-up study of patients with rheumatoid arthritis over a period of more than 10 years (1966-1978): analysis of disease progression and treatment in 100 cases (author's translation). Ann. Med. Interne., 1981, 132, 168-173.
3. Arnold M.H., Janssen B., Schrieber L. i wsp.: Prospective pilot study of intravenous pulse cyclophosphamide therapy for refractory rheumatoid arthritis. Arthritis Rheum., 1989, 32, 933-934.
4. Arnold H. Bourseaux F.: Synthese und Abbau cytostatisch wirksamer cyclisher N?Phosphamidester des Bis? (b-clorathyl) - amins. Angewandte Chemie, 1958, 70, 539-544.
5. Bagley C.M. Jr, BosVita V.T. Jr., Tick F.W.: Clinical pharmacology of cyclophosphamide. Cancer Res., 1973, 33, 226-233.
6. Baker G.L., Kahl LE, Zee B.C. i wsp.: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am. J. Med., 1987, 83, 1-9.
7. Baltus J.A., Boersma J.W., Hartman A.P. i wsp.: The occurrence of melignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann. Rheum. Dis., 1983, 42, 4, 368-373.
8. Bryant B.M., Jarman M., Ford H.T. i wsp.: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet, 1980, 2, 657-659.
9. Chevrel G., Jenvrin C., McGragor B. i wsp.: Renal type amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide, 2001, 40, 7, 821-825.
10. Clements P.J.: Alkylating agents. In: Second line agents in the treatment of rheumatic diseases (eds. Dixon J., Furst D.E.). New York. Marcel Dekker. 1992.
11. Clements P.J., Yu D.T., Levy J. i wsp.: Effects of cyclophosphamide on B- and T lymphocytes in rheumatoid arthritis. Arthritis Rheum., 1974, 17, 4, 347-353.
12. Cohen JL, Jao JY, Jusko WJ. Pharmacokinetics of cyclophosphamide in man. Br. J. Pharmacol., 1971, 43, 3, 677-680.
13. Diamanstein T., Willinger E., Reiman J.: T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4- hydroperoxycyclophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. A direct proof for different sensitivities of lymphocyte subsets to cyclophosphamide. J. Exp. Med., 1979, 150, 6, 1571.
14. Diaz C.J., Garcia E.L., Mechante A.: Treatment of rheumatoid arthritis with nitrogen mustard. Preliminary report. JAMA, 1951, 147, 1418-1419.
15. Ehrlich R.M., Freedman A., Goldsobel A.B. i wsp.: The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis. J. Ural., 1984, 131, 960-962.
16. Fairley K.F., Barrie J.U., Johnson W.: Sterility and testicular atrophy related to Cyclophosphamide therapy. Lancet, 1972, 1, 7750, 568-569.
17. Falck H.M., Maury C.P.J., Teppo A.M. i wsp.: Correlation of persistently high serum amyloid A protein and C - reactive protein concentrations with rapid progression of secondary amyloidosis. Br. Med. J., 1983, 286, 1391-1393.
18. Ferguson R.M., Simmons R.L.: Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors. Transplantation, 1978, 25, 1, 36-38.
19. Fort J.G., Abruzzo J.L.: Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednizolone. Arthritis Rheum., 1988, 31, 1194-1198.
20. Gertz M.A., Kyle R.A.: Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine (Baltimore). 1991, 70, 246-256.
21. Greenberg L.H., Tanaka K.R.: Congenital anomalies probably induced by cyclophosphamide. JAMA, 1964, 188, 423-426.
22. Horslev-Petersen K., Beyer J.M, Helin P.: Intermittent cyclophosphamide in refractory rheumatoid arthritis. Br. Med. J., 1983, 287, 711-712.
23. Hows J.M., Mehta A., Ward L. i wsp.: Comparison of mesna with forced diuresis to prevent Cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br. J. Cancer, 1984, 50, 753-756.
24. Husebekk A., Skogen B., Husby G.: Transformation of amyloid precursor protein SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand. J. Immunol., 1985, 21, 283-287.
25. Johnson W.W., Meadows D.C.: Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. N. Engl. J. Med., 1971, 284, 6, 290-294.
26. Kawabatta T.T., Chapman M.Y., Kim D.H. i wsp.: Mechanisms of in vitro immunosuppression by hepatocyte - generated cyclophosphamide metabolites and 4-hydroperoxycyclophosphamide. Biochem. Pharmacol. 1990, 40, 927-935.
27. Kinlen L.J.: Incidence of cancer in rheumatoid arthritis and other disorders after Immunosuppressive treatment. Am. J. Med., 1985, 78: 44-49.
28. Kirshon B., Wasserstrum N., Willis R., Herman G.E. i wsp.: Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet. Gynecol., 1988, 72, 3 Pt 2, 462-464.
29. Klippel J.H.: Cyclophosphamide: ovarian and other toxicities. Lupus, 1995, 4, 1, 1-2.
30. Kumar R., Biggart J.D., Mc Evoy J. i wsp.: Cyclophosphamide and reproductive function. Lancet, 1972, 1, 1212-1214.
31. Kovarsky J.: Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin. Arthritis Rheum., 1983, 12, 359-372.
32. Laing T.J.: Gastrointestinal vasculitis andpneumatosis intestinalis due to systemic lupus erythomatosus: successful treatment with pulse intravenous cyclophosphamide. Am. J. Med., 1988, 85, 555-558.
33. Ła̧cki J.K., Leszczyński P., Mackiewicz S.H.: Intravenous cyclophosphamide combined with methylprednisolone in the treatment of severe refractory rheumatoid arthritis: the effect on lymphocytes. J Investing Aler gol. Clin. Immunol., 1996, 6, 4, 232-236.
34. Ła̧cki J.K., Wassmuth R., Korczowska I. : wsp.: The presence of HLA-DR B1 shared motif does not influence cyclophosphamide and methotrexate cytotoxicity in rheumatoid arthritis patients J. Investing. Alergol. Clin. Immunol., 2000, 10, 4, 235-241.
35. Masala A., Faedda R., Alagna S. i wsp.: Use of testosterone to prevent cyclophosphamide- induced azoospermia. Ann. Intern. Med., 1997, 126: 292-295.
36. Parsons C.L.: Bladder surface glycosaminoglycan: efficient mechanism of Environmental adaptation. Urology, 1986, 27, 9-14.
37. Radis C.D., Kahl L.E., Baker G.L. i wsp.: Effects of cyclophosphamide on development of melignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follwup study. Arthritis Rheum., 1995, 38, 8, 1120-1127.
38. Renier J.C., Bregeon C., Bonnette C. i wsp.: Evolution of patients with rheumatoid arthritis treated with immunosuppressive agents between 1965 and 1973. Rev Rheum. Mal. Osteoartic., 1978, 45, 7-9, 453-461.
39. Schein P.S., Winokur S.H.: Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann. Intern. Med., 1975, 82, 1, 84-95.
40. Scott D.G., Bacon P.A.: Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am. J. Med., 1984, 76, 377-384.
41. Sokal J.E., Lessmann E.M.: Effects of cancer chemotherapeutic agents on the human fetus. JAMA. 1960, 172, 1765-1777.
42. Townes A.S., Sowa J.M., Shulman L.E.: Controlled trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum., 1976, 19, 563-570.
43. Turk J.L., Poulter L.W.: Selective depletion of lymphoid tissue by cyclophosphamide. Clin. Exp. Immunol., 1972, 10, 285-296.
44. Williams H.J., Reading J.C., O'Brien W.M. i wsp.: Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum., 1980, 23, 5, 521-527.